Dr Reddy's Laboratories Ltd (NYSE:RDY)
| 53.83 Delayed Data As of Feb 02 |  -0.05 / -0.09%Today’s Change | 47.88 Today|||52-Week Range 58.98 | +4.02% Year-to-Date |
Latest RDY News | Press Releases
| Dr. Reddy's (RDY) Q3 Earnings & Revenues Beat Estimates Jan 27 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 53.88 |
| Today’s open | 53.92 |
| Day’s range | 53.36 - 53.92 |
| Volume | 235,183 |
| Average volume (3 months) | 213,750 |
| Market cap | $8.9B |
Data as of 3:59pm ET, 02/02/2023
Growth & Valuation
| Earnings growth (last year) | +36.18% |
| Earnings growth (this year) | +55.53% |
| Earnings growth (next 5 years) | +21.15% |
| Revenue growth (last year) | +12.59% |
| P/E ratio | 20.2 |
| Price/Sales | 3.22 |
| Price/Book | 3.52 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| JAZZJazz Pharmaceuticals... | -1.37 | -0.87% |
| CTLTCatalent Inc | +0.01 | +0.02% |
| SRPTSarepta Therapeutics... | -2.11 | -1.72% |
| RGENRepligen Corp | +4.39 | +2.30% |
Data as of 3:59pm ET, 02/02/2023
Financials
| Next reporting date | May 12, 2023 |
| EPS forecast (this quarter) | $0.68 |
| Annual revenue (last year) | $2.9B |
| Annual profit (last year) | $316.3M |
| Net profit margin | 10.99% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Hyderabad, Telangana |
Forecasts
